DOCSLIB.ORG

2018-404 SML Redacted.Pdf

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
2018-404 SML Redacted.Pdf IMG Ustav molekularnf genet iky AV CR, v. v. i. KUPNI SMLOUVA kterou nfze uvedeneho dne, mesfce a roku v souladu s ustanovenfm § 2079 a nasl. zakona c. 89/2012 Sb., obcansky zakonfk, v platnem znenf uzavreli Scintila, s.r.o. jako prodavajfcf a Ustav molekularnf genetiky AV CR, v. v. i. jako kupujfcf Videriska 1083, lll2 20 Praha I ~ IMG Ustav molekularnf genetiky AV CR. v. v. i. ------------------- ------ Smluvnl strany: Nazev (obchodnf firma): Scintila, s.r.o. ICO: 25557858 Sfdlo/Mfsto podnikanf: Ovoz 173/18, 586 01 Jihlava • DIC: CZ25557858 Zastoupeny/a: Ivana Rejtharkova, jednatelka Bankovni spojenf: zapsana v obchodnfm rejstrfku vedenem u Krajskeho soudu v Brne odd fl c vlozka 33195 (dale jen ,,prodavajfcf") a Nazev: Ostav molekularni genetiky AV CR, v. v. i. ICO: 68378050 DIC : CZ68378050 Sid lo: Vfdenska 1083, 142 20 Praha 4 Zastoupena: RNDr. Petr Draber, DrSc., reditel Zapsana v rejstrfku vei'ejnych vyzkumnych institud (dale jen ,,kupujid") (dale spolecne tez ,,smluvni strany") se v souladu s ustanovenim § 2079 a nasl. zakona c. 89/2012 Sb ., obcansky zakonfk, v platnem zneni, dohodly nfze uvedeneho dne, mesfce a roku tak, jak stanovi tato Kupnl smlouva Preambule 1. Smluvnf strany shodne prohlasujf, ze tuto smlouvu uzavfrajf na zaklade zadavadho rfzenf pro podlimitnf verejnou zakazku pod evidenenfm cfslem UMG 2018-204 v souladu s pravidly pro zadavanf verejnych zakazek. 2. Podkladem pro uzavrenf teto smlouvy je nabfdka Poskytovatele podana na zaklade vyzvy k podanf nabidky, a to pro verejnou zakazku nazvanou Soubor bioaktivnich latek 2018 - 1. cast Soubor bioaktivnfch latek 2018 A (dale jen ,,verejna zakazka"), zadavanou v souladu se zakonem c. 134/2016 Sb., o zadavanf verejnych zakazek, ve zneni pozdejsfch predpisu (dale jen ,,ZZVZ"). Smluvnf strany sjednavaji, ze veskere zadavad podmf nky stanovene v ramci shora uvedene vei'ejne zakazky jsou soucasti sm luvnfch podminek die teto smlouvy. 3. Prodavajid bere na vedomi, ze s ohledem na to, ze kupujid je verejnou v')izkumnou institud hospodai'fd s verejnymi prosti'edky, je prodavajid osobou povinnou spolupusobit pri vykonu financni kontroly ve smyslu zakona c. 320/2001 Sb., o financni kontrole ve verejne sprave a o 2 ~ IMG Ustav molekularnf genetiky AV CR. v. v. i. ------------ zmene nekter'{ch zakonu (zakon 0 financnf kontrole). 4. Prodavajid dale prohlasuje, ze si je vedom povinnostf a nasledku vyplyvajfdch ze zakona c. 340/2015 Sb., o registru smluv ve znenf pozdejsich predpisu, kdy kupujfd je verejnou vyzkumnou institud, a tfmto vyslovne souhlasf s uverejnenfm teto smlouvy v registru smluv, pricemz pro ucely uverejnenf smlouvy nepovafoji smluvnf strany nic z obsahu teto smlouvy ani z metadat k nf se vazfdch za vyloucene z uverejneni. 5. Prodavajid prohlasuje, fo je platce DPH. 6. Smluvnf strany prohlasuji, Ze pred uzavrenfm teto smlouvy radne splnily vsechny hmotnepravnf podmfnky pro platne uzavrenf teto smlouvy vyplyvajid z platnych pravnich predpisu, jakoz i z jejich platnych vnitrnfch predpisu, a dale prohlasujf, ze uzavrenfm teto smlouvy nedojde k porusenf jakychkoliv jejich zakonnych ci smluvnich povinnosti. 7. Prodavajid vyslovne prohlasuje, Ze predmet plneni splr'\uje prfslusna ustanovenf zakona c. 22/1997 Sb., o technickych pofadavdch na vyrobky a o zmene a doplnenf nekterych zakonu, v platnem zneni. Clanek 1 Predmet smlouvy 1. Predmetem teto smlouvy je povinnost prodavajfdho dodat 278 kusu bioaktivnlch latek, pricemz plnenf je blize specifikovano nize v odst. 2 tohoto clanku a da le v pi'iloze c. 1 teto smlouvy -Technicka specifikace predmetu plnenf, seznam poptavanych latek a v pi'iloze c. 2 teto smlouvy - Seznam, popis a specifikace nabfzenych latek (dale jen ,,predmet plnenf"), a kupujfd se zavazuje predmet plnenf prevzft a uhradit prodavajfcimu kupn f cenu specifikovanou v clanku 2 teto smlouvy. 2. Prodavajici prohlasuje, Ze predmet plnenf splnuje tyto technicke podmfnky a pofadavky: );;;>- dodavka souboru minimalne 70 % z celkoveho poctu 397 poptavanych unikatnfch chemickych latek die technicke specifikace, ktera je prilohou c. 1 teto smlouvy; );;;>- naplnenf chemickych latek do zkumavek ve stojancich: • dodanf chemickych latek ve formatu 96 jamek. Latky budou naplneny do bezbarvych polypropylenovych zkumavek o objemu 1 ml se sroubovacimi vfcky a 2D carovymi k6dy (format DataMatrix) na jejich dne, ktere ma tvar ,,V" (Thermo Scientific™ Matrix™ l.OmL ScrewTop Tubes). Zkumavky budou ulozeny v plastovych ANSI k6dovanych stojancich (Matrix 2D Barcoded Screw Top Storage Tubes & Caps) s uzamykatelnym vfkem pro vyse uvedene zkumavky; • Plnenf do zkumavek ve stojancich po sloupcich c. 1 az c. 11. ve smeru Al az Hl, A2 az H2, ... , All az Hll. Posledni sloupec c. 12 bude ponechan prazdny, tzn. v kazdem stojanku bude maximalne 88 zkumavek s chemickymi latkami; • Dodanf kazde jednotlive dilCi latky v pevnem skupenstvf a mnozstvf 5-10 µmol (tj. presne navazene mnozstvf, ktere po pi'idanf rozpoustedla (DMSO) poskytne 500-1000 µI roztoku o koncentraci 0,01 mol x dm-3; ---- - --------- 3 ~ IMG Ustav molekularn l genetiky AV CR, v. v. i. ---------------------- );>- dodanf na adresu Kupujfciho; );>- dorucenf elektronicke dokumentace k souboru latek Prodavajfcim nejpozdeji v okamziku dodani predmetu plnenf. Elektronickou dokumentaci se rozumf: • Textovy soubor pro mapovanf souboru latek ve formatu XLSX obsahujfci minimalne tyto informace ke kazde latce: id (= unikatnf internf identifikator latky od prodavajfciho), source (= nazev prodavajfciho - presny format bude zadavatelem upresnen po oboustrannem podpisu smlouvy), platename (= Cfselne nebo slovnf oznacenf stojanku), position (= pozice/souradnice zkumavky s latkou ve stojanku), barcode (= 2D carovy k6d zkumavky), smiles (jednoznacny popis molekularnf struktury latky pomoci Fetezcu znaku ASCII ve formatu SMILES), purity (cistota latky stanovena na zaklade LC/MS, GC/MS nebo lH-NMR), weight (presne navafona hmotnost praskove substance s presnostf na desetiny mg). V prfpade dodanf latky ve forme farmaceuticky akceptovatelne soli, bude struktura latky obsahovat kompletnf molekulu, tzn. kationt i aniont. Prodavajfci mufo volitelne pridat dalsf relevantnf data k jednotlivym latkam, jako je napr. CAS cfslo, trivia Inf jmeno, katalogove cfslo, rozpustnost, atd. • PFfslusna analyticka data pro kazdou chemickou latku dokazujfci jejf Cistotu (chromatogramy nebo NMR spektra), pro kterou jsou tyto data k dispozici. Cistota kazde chemicke slouceniny bude Cinit minimalne 90 % na zaklade LC/ MS (PDA mei'enf v rozsahu 200-400 nm a/nebo ELSD), GC/MS nebo lH-NMR. Data budou ulozena v jednotlivych souborech formatu PDF o maximalnf velikosti 100 kB. Kazdy soubor bude pojmenovan dodrzenfm standardizovaneho syntaxu: ,,id_source_analysis-data.pdf" (id = internf identifikator latky od prodavajfcfho - stejny jako v mapovacim souboru XLSX, source =nazev prodavajfciho, presny format bude upresnen). • Prodavajfci ulozf elektronickou dokumentaci na CD-ROM (DVD), kter'{ bude oznacen nazvem ,,Elektronicka dokumentace", ,,Soubor bioaktivnfch latek 2018 1. cast Soubor bioaktivnfch latek 2018 A", nazvem a identifikacnfmi udaji prodavajfciho. Podrobna technicka specifikace predmetu plnenf je uvedena v pFilohach c. 1 a 2 teto smlouvy, ktere tvorf nedflne soucasti teto smlouvy. 3. Predmetem plnenf die teto smlouvy je: naplnenf bioaktivnich latek do zkumavek ve stojancich Prodavajfcim die technicke specifikace uvedene v pi'flohach c. 1 a 2 teto smlouvy; dodanf predmetu plnenf v mfste plnenf a case a zpusobem die clanku 4 teto smlouvy; predanf elektronicke dokumentace konkretnich bioaktivnfch latek dodavaneho pi'edmetu plnenf na CD Ramu nebo pamefovem nosici dat (flash disk) a vytisteneho Seznamu nabfzenych latek die odst. 2 tohoto clanku vyse Prodavajfcim nejpozdeji v okamziku dodanf predmetu plnenf; poskytnutf zaruky za jakost die clanku 5 teto smlouvy. Clanek 2 Kupnf cena 1. Smluvnf strany se dohodly, ze kupnf cena za pi'evod vlastnickeho prava k pi'edmetu plnenf specifikovanemu v clanku 1 teto smlouvy (tj. za radne dodany pocet 278 kusu bioaktivnfch latek bez vad) cinf: 4 ~ IMG Ustav mo lekularnf genetiky AV CR. v. v. i. ------------ ---- - --- -------- Celkova cena bez DPH: 479900 Kc DPH 21 % 100779 Kc /vyplnf pouze ucastnfk, kte,.Y je platcem DPH/ Celkova cena s DPH 580679 Kc /vyplni pouze ucastnfk, kte,.Y je platcem DPH/ (dale jen ,,Kupnf cena") 2. vyse Kupnf ceny je zasadne neprekrocitelna. Kupni cenu je mofoe prekrocit pouze v prfpade, ze v prubehu plnenf predmetu teto smlouvy dojde ke zmenam sazeb dane z pridane hodnoty. Rozhodnym dnem je den uskutecnenf zdanitelneho plnenf. 3. Kupnf cena v sobe zahrnuje veskere prace a dodavky nezbytne pro radne splnenf predmetu teto smlouvy, veskere naklady spojene s uplnym dodanim predmetu plnenf a naklady na dopravu do mfsta plnenf, jakoz i veskere dalsf naklady souvisejfd s predmetem plnenf a souvisejidmi cinnostmi die clanku 1 odst. 3 smlouvy. 4. Kupni smlouva v sobe dale zahrnuje zaruku za jakost, ktera je specifikovana v clanku 5 teto smlouvy. 5. Kupnf cena bude hrazena bez poskytovani zaloh. Clanek 3 Platebnf podminky 1. Smluvnf strany se dohodly, ze cela Kupnf cena bude uhrazena po radnem predanf predmetu plnenf (tj. bez jakychkoli vad a nedodelku) v mfste plnenf uvedenem v clanku 4 odst. 2 teto smlouvy. 0 radnem dodanf predmetu plnenf bude sepsan pfsemny predavad protokol podepsany obema smluvnfmi stranami. 2. Kupujfcf se zavazuje uhradit Kupnf cenu na zaklade faktury vystavene prodavajfdm, kterou kupujicf predem odsouhlasf, se splatnostf 30 dnu ode dne vystavenf. Faktura se pro ucely teto smlouvy
Load more

Recommended publications
  • Emerging Pharmacological Strategies for the Treatment
    Emerging pharmacological strategies for the treatment of fibromyalgia LAWSON, Kim Available from Sheffield Hallam University Research Archive (SHURA) at: http://shura.shu.ac.uk/15300/ This document is the author deposited version. You are advised to consult the publisher's version if you wish to cite from it. Published version LAWSON, Kim (2017). Emerging pharmacological strategies for the treatment of fibromyalgia. World Journal of Pharmacology, 6 (1), 1-10. Repository use policy Copyright © and Moral Rights for the papers on this site are retained by the individual authors and/or other copyright owners. Users may download and/or print one copy of any article(s) in SHURA to facilitate their private study or for non- commercial research. You may not engage in further distribution of the material or use it for any profit-making activities or any commercial gain. Sheffield Hallam University Research Archive http://shura.shu.ac.uk World Journal of WJ P Pharmacology Submit a Manuscript: http://www.wjgnet.com/esps/ World J Pharmacol 207 March 9; 6(): -0 DOI: 0.5497/wjp.v6.i. ISSN 2220-392 (online) MINIREVIEWS Emerging pharmacological strategies for the treatment of ibromyalgia Kim Lawson Kim Lawson, Department of Biosciences and Chemistry, Bio­ presenting with a complex of symptoms dominated by molecular Sciences Research Centre, Shefield Hallam University, chronic widespread pain associated with the existence of a Faculty of Health and Wellbeing, Sheffield S1 1WB, United range of co-morbidities, such as fatigue, sleep disturbance, Kingdom cognitive impairment, anxiety and depression. Current treatments include drugs that target serotonin and nor- Author contributions: Lawson K researched the materials for the article and wrote the manuscript.
    [Show full text]
  • G Protein-Coupled Receptors
    S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2015/16: G protein-coupled receptors. British Journal of Pharmacology (2015) 172, 5744–5869 THE CONCISE GUIDE TO PHARMACOLOGY 2015/16: G protein-coupled receptors Stephen PH Alexander1, Anthony P Davenport2, Eamonn Kelly3, Neil Marrion3, John A Peters4, Helen E Benson5, Elena Faccenda5, Adam J Pawson5, Joanna L Sharman5, Christopher Southan5, Jamie A Davies5 and CGTP Collaborators 1School of Biomedical Sciences, University of Nottingham Medical School, Nottingham, NG7 2UH, UK, 2Clinical Pharmacology Unit, University of Cambridge, Cambridge, CB2 0QQ, UK, 3School of Physiology and Pharmacology, University of Bristol, Bristol, BS8 1TD, UK, 4Neuroscience Division, Medical Education Institute, Ninewells Hospital and Medical School, University of Dundee, Dundee, DD1 9SY, UK, 5Centre for Integrative Physiology, University of Edinburgh, Edinburgh, EH8 9XD, UK Abstract The Concise Guide to PHARMACOLOGY 2015/16 provides concise overviews of the key properties of over 1750 human drug targets with their pharmacology, plus links to an open access knowledgebase of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of target and ligand properties. The full contents can be found at http://onlinelibrary.wiley.com/doi/ 10.1111/bph.13348/full. G protein-coupled receptors are one of the eight major pharmacological targets into which the Guide is divided, with the others being: ligand-gated ion channels, voltage-gated ion channels, other ion channels, nuclear hormone receptors, catalytic receptors, enzymes and transporters. These are presented with nomenclature guidance and summary information on the best available pharmacological tools, alongside key references and suggestions for further reading.
    [Show full text]
  • GPCR/G Protein
    Inhibitors, Agonists, Screening Libraries www.MedChemExpress.com GPCR/G Protein G Protein Coupled Receptors (GPCRs) perceive many extracellular signals and transduce them to heterotrimeric G proteins, which further transduce these signals intracellular to appropriate downstream effectors and thereby play an important role in various signaling pathways. G proteins are specialized proteins with the ability to bind the nucleotides guanosine triphosphate (GTP) and guanosine diphosphate (GDP). In unstimulated cells, the state of G alpha is defined by its interaction with GDP, G beta-gamma, and a GPCR. Upon receptor stimulation by a ligand, G alpha dissociates from the receptor and G beta-gamma, and GTP is exchanged for the bound GDP, which leads to G alpha activation. G alpha then goes on to activate other molecules in the cell. These effects include activating the MAPK and PI3K pathways, as well as inhibition of the Na+/H+ exchanger in the plasma membrane, and the lowering of intracellular Ca2+ levels. Most human GPCRs can be grouped into five main families named; Glutamate, Rhodopsin, Adhesion, Frizzled/Taste2, and Secretin, forming the GRAFS classification system. A series of studies showed that aberrant GPCR Signaling including those for GPCR-PCa, PSGR2, CaSR, GPR30, and GPR39 are associated with tumorigenesis or metastasis, thus interfering with these receptors and their downstream targets might provide an opportunity for the development of new strategies for cancer diagnosis, prevention and treatment. At present, modulators of GPCRs form a key area for the pharmaceutical industry, representing approximately 27% of all FDA-approved drugs. References: [1] Moreira IS. Biochim Biophys Acta. 2014 Jan;1840(1):16-33.
    [Show full text]
  • Drug Delivery System for Use in the Treatment Or Diagnosis of Neurological Disorders
    (19) TZZ __T (11) EP 2 774 991 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 10.09.2014 Bulletin 2014/37 C12N 15/86 (2006.01) A61K 48/00 (2006.01) (21) Application number: 13001491.3 (22) Date of filing: 22.03.2013 (84) Designated Contracting States: • Manninga, Heiko AL AT BE BG CH CY CZ DE DK EE ES FI FR GB 37073 Göttingen (DE) GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO •Götzke,Armin PL PT RO RS SE SI SK SM TR 97070 Würzburg (DE) Designated Extension States: • Glassmann, Alexander BA ME 50999 Köln (DE) (30) Priority: 06.03.2013 PCT/EP2013/000656 (74) Representative: von Renesse, Dorothea et al König-Szynka-Tilmann-von Renesse (71) Applicant: Life Science Inkubator Betriebs GmbH Patentanwälte Partnerschaft mbB & Co. KG Postfach 11 09 46 53175 Bonn (DE) 40509 Düsseldorf (DE) (72) Inventors: • Demina, Victoria 53175 Bonn (DE) (54) Drug delivery system for use in the treatment or diagnosis of neurological disorders (57) The invention relates to VLP derived from poly- ment or diagnosis of a neurological disease, in particular oma virus loaded with a drug (cargo) as a drug delivery multiple sclerosis, Parkinsons’s disease or Alzheimer’s system for transporting said drug into the CNS for treat- disease. EP 2 774 991 A1 Printed by Jouve, 75001 PARIS (FR) EP 2 774 991 A1 Description FIELD OF THE INVENTION 5 [0001] The invention relates to the use of virus like particles (VLP) of the type of human polyoma virus for use as drug delivery system for the treatment or diagnosis of neurological disorders.
    [Show full text]
  • Computational Modeling of Gpcrs: Towards Understanding Receptor Signaling for Biology and Drug Discovery
    Computational Modeling of GPCRs: Towards Understanding Receptor Signaling for Biology and Drug Discovery Vsevolod (Seva) Katritch JCIMPT-ComplexesBarcelona, | January Jul 13 7,th 2011, 2018 1 GPCRs in Human Biology & Pharmacology Nat Rev Drug Disc 5:993 (2006) >30% of all drugs GPCR targets GPCR Targets: >120 established > 800 potential 800 GPCR are receptors for: Disorders Targeted Clinically Neurotransmitters ( adrenaline, dopamine, Psychiatric, Learning & Memory, histamine, acetylcholine, adenosine, Mood, Sleep, Drug Addiction, Stress, serotonin, glutamate, anandamide, GABA) Anxiety, Pain, Social Behavior… Hormones & Neuropeptides (opioid, neurotensin, glucagon, CRF, Cardiovascular, Endocrine, Obesity, galanin, orexin, oxytocin, neuromedin, Immune, HIV, Reproductive … melanocortins, somatostatin, ghrelin, TRH, TSH, GnRH, , PTH, THS, LH… >30 total ) Neurodegenerative and Autoimmune Disease … Immune system (chemokine, sphingosine 1 phosphate) Brain Development, Regenerative Med. Development (Frizzled, Adhesion) Sensory Cancer Light, Taste, Olfactory (388) GPCR Structure and Function Thousands of Ligands - Chemical Diversity >800 Different Human Receptors (largest family in human genome) Share 7TM Fold But Diverse We use structure Structural and modeling Features to learn: • Molecular Recognition • Signaling Mechanisms and to design: Dozens of Effectors New tool compounds GPCR New receptor properties Consortium Katritch et al 2013 Annu Rev Pharm. Tox. 53, 531-556 Stevens et al. 2013, Nat Rev Drug Discov, 12: 25–34 Outline ➢Rational prediction of stabilizing mutations: CompoMug ➢New insights into GPCR function and allosteric mechanisms ➢Structure-Based ligand discovery for GPCRs 5 Why Stabilizing GPCRs? ➢ Crystallography: ➢ Synergistic with fusions and truncations ➢ Reduces heterogeneity ➢ Allows stabilization of active or inactive states ➢ Allows co-crystallization with low-affinity ligands ➢ Biophysical characterization ➢ SPR ➢ NMR ➢ Drug discovery ➢ More robust assays for HTS Navratilova et al.
    [Show full text]
  • Recent Advances in Pain Management
    International Journal of Basic & Clinical Pharmacology Ba skaran P et al. Int J Basic Clin Pharmacol. 2021 Jan;10(1):133-139 http:// www.ijbcp.com pISSN 2319-2003 | eISSN 2279-0780 DOI: https://dx.doi.org/10.18203/2319-2003.ijbcp20205553 Review Article Recent advances in pain management Priyadarsini Baskaran1, Venkatraman Karthikeayan2, Anusha Natarajan3* 1Medical Monitor, Clinirx CRO, Chennai, Tamil Nadu, India 2Consultant Neuro-Immunologist, Global Hospitals, Chennai , Tamil Nadu, India 3Department of Pharmacology, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry, India Received: 26 May 2020 Revised: 01 December 2020 Accepted: 12 December 2020 *Correspondence: Dr. Anusha Natarajan, Email: [email protected] Copyright: © the author(s), publisher and licensee Medip Academy. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. ABSTRACT Pain is one of the most common complaints for which patients approach physicians. In spite of this there is a huge unmet need for developing medications for pain that are safe and efficacious. Owing to the heterogeneity of clinical pain and complex pathophysiology, target identification for drug development is difficult. Preclinical models have also proven unreliable for the development of novel analgesics. Recent advances in understanding the physiology of nociception has enabled the development of novel analgesics including abuse deterrent opioids, drugs targeting several receptors, ion channels and enzymes. This review will attempt to cover the physiology of nociception focusing on the novel targets, the challenges in development of novel analgesics and give an overview of the recently developed drugs and those in the pipeline for the management of pain.
    [Show full text]
  • NDO Home | Contact | Register for NDO Access
    NNeewwsslleetttteerr Highlights of updates to NDO in February 2014 NDO home | Contact | Register for NDO access in Prescribing Regulatory changes in the EU Outlook 2013 Launched in the UK Botulinum toxin A (Botox) Stroke-associated ankle disability [licence extension] Canagliflozin (Invokana) Type 2 diabetes mellitus in adults Cobicistat (Tybost) HIV infection in adults Dimethyl fumarate (Tecfidera) Multiple sclerosis, relapsing-remitting Dolutegravir (Tivicay) HIV infection in adults and adolescents from age 12 years Elvitegravir (Vitekta) HIV infection in adults Lipegfilgrastim (Lonquex) Chemotherapy-induced neutropenia Sofosbuvir (Sovaldi) Hepatitis C infection in adults Solifenacin + tamsulosin (Vesomni) Benign prostatic hyperplasia-associated lower urinary tract symptoms [new formulation] Ulipristal (Esmya) Uterine fibroids – repeat three-month treatment course after previous pre-operative treatment of moderate to severe symptoms [licence extension] Approved in the EU Autologous cultured chondrocytes Full-thickness cartilage defects of the knee in adults (MACI) Brimonidine (Mirvaso) Rosacea facial erythema in adults [new formulation] Ethinylestradiol + gestodene Contraception [transdermal formulation] Somatropin Growth hormone deficiency [once-weekly formulation] EU positive opinions Budesonide + formoterol (DuoResp Asthma and chronic obstructive pulmonary disease [new formulation] Spiromax) Canagliflozin + metformin IR Type 2 diabetes mellitus (Vokanamet) Elosulfase alfa (Vimizim) Mucopolysaccharidosis IVA (Morquio syndrome) Follicle
    [Show full text]
  • Emerging Pharmacological Strategies for the Treatment of Fibromyalgia
    Emerging pharmacological strategies for the treatment of fibromyalgia LAWSON, Kim <http://orcid.org/0000-0002-5458-1897> Available from Sheffield Hallam University Research Archive (SHURA) at: http://shura.shu.ac.uk/15300/ This document is the author deposited version. You are advised to consult the publisher's version if you wish to cite from it. Published version LAWSON, Kim (2017). Emerging pharmacological strategies for the treatment of fibromyalgia. World Journal of Pharmacology, 6 (1), 1-10. Copyright and re-use policy See http://shura.shu.ac.uk/information.html Sheffield Hallam University Research Archive http://shura.shu.ac.uk World Journal of W J P Pharmacology Submit a Manuscript: http://www.wjgnet.com/esps/ World J Pharmacol 207 March 9; 6(): -0 DOI: 0.5497/wjp.v6.i. ISSN 2220-392 (online) MINIREVIEWS Emerging pharmacological strategies for the treatment of fibromyalgia Kim Lawson Kim Lawson, Department of Biosciences and Chemistry, Bio­ presenting with a complex of symptoms dominated by molecular Sciences Research Centre, Sheffield Hallam University, chronic widespread pain associated with the existence of a Faculty of Health and Wellbeing, Sheffield S1 1WB, United range of co-morbidities, such as fatigue, sleep disturbance, Kingdom cognitive impairment, anxiety and depression. Current treatments include drugs that target serotonin and nor- Author contributions: Lawson K researched the materials for adrenaline levels within the central nervous system, e.g., the article and wrote the manuscript. tricyclic antidepressants, serotonin noradrenaline reuptake Conflict-of-interest statement: There is no conflict of interest inhibitors, and voltage-gated calcium channel subunit associated with the author for the contributions in this manuscript.
    [Show full text]
  • 2015 Medicines in Development for Neurological Disorders a Report on Disorders of the Brain, Spinal Cord and Nerves
    2015 Medicines in Development for Neurological Disorders A Report on Disorders of the Brain, Spinal Cord and Nerves Alzheimer's Disease Product Name Sponsor Indication Development Phase AC-1204 Accera mild to moderate Alzheimer's disease Phase II/III (caprylic triglyceride) Broomfield, CO www.accerapharma.com ACI-35 AC Immune Alzheimer's disease Phase I (active anti-Tau vaccine) Lausanne, Switzerland www.acimmune.com Janssen Research & Development www.janssenrnd.com Raritan, NJ AD-4833/TOMM40 Takeda Pharmaceutical delay onset of mild cognitive Phase III (insulin sensitizer) Deerfield, IL impairment due to Alzheimer's www.takeda.com Zinfandel Pharmaceuticals disease Chapel Hill, NC aducanumab (BIIB037) Biogen Alzheimer's disease Phase I (amyloid beta-protein inhibitor) Cambridge, MA www.biogen.com ALZ-801 Alzheon Alzheimer's disease Phase I (amyloid beta-protein inhibitor) Framingham, MA www.alzheon.com ANAVEX Plus Anavex Life Sciences Alzheimer's disease Phase II (ANAVEX 2-73/donepezil) New York, NY www.anavex.com ASP3662 Astellas Pharma US Alzheimer's disease Phase I Northbrook, IL www.astellas.us Alzheimer's Disease Product Name Sponsor Indication Development Phase AVN-101 AllaChem Alzheimer's disease Phase II (serotonin 6 receptor antagonist) Hallandale, FL www.allachem.com Avineuro Pharmaceuticals San Diego, CA AVN-322 AllaChem Alzheimer's disease Phase II (serotonin 6 receptor antagonist) Hallandale, FL www.allachem.com Avineuro Pharmaceuticals San Diego, CA AVP-786 Avanir Pharmaceuticals agitation in Alzheimer's disease Phase I
    [Show full text]
  • Autoantikörper-Induzierte Effekte Des Angiotensin II-Rezeptors Typ 1 Und
    Autoantikörper-induzierte Effekte des Angiotensin II-Rezeptors Typ 1 und des Endothelinrezeptors Typ A auf humane periphere mononukleäre Zellen und ihre Relevanz bei der Pathogenese der systemischen Sklerose vorgelegt von Master of Science Jeannine Günther geb. in Berlin von der Fakultät III – Prozesswissenschaften der Technischen Universität Berlin zur Erlangung des akademischen Grades Doktor der Naturwissenschaften - Dr. rer. nat. - genehmigte Dissertation Promotionsausschuss: Vorsitzender: Prof. Dr. Stephan Pflugmacher Lima Gutachter: Prof. Dr. Roland Lauster Gutachterin: Prof. Dr. Gabriela Riemekasten Gutachter: Prof. Dr. Jens Kurreck Tag der wissenschaftlichen Aussprache: 30. Januar 2017 Berlin 2017 Für Timo Inhaltsverzeichnis Inhaltsverzeichnis Inhaltsverzeichnis ........................................................................................................................... 3 Zusammenfassung .......................................................................................................................... 8 Abstract ........................................................................................................................................... 9 Abkürzungsverzeichnis ................................................................................................................. 10 1 Einleitung ............................................................................................................................... 13 1.1 Autoimmunität und Autoantikörper .............................................................................
    [Show full text]
  • Neurological Disorders
    2013 MEDICINES IN DEVELOPMENT REPORT Neurological Disorders A Report on Disorders of the Brain, Spinal Cord and Nerves PRESENTED BY AMERICA’s biopharmACEUTICAL RESEARCH COMPANIES Biopharmaceutical Companies Researching and Developing Nearly 450 Medicines for Neurological Disorders Neurological disorders—such as epi- Other medicines in development target lepsy, multiple sclerosis and Parkinson’s amyotrophic lateral sclerosis (ALS), disease—inflict great pain and suffering brain injuries, Huntington’s disease, on patients and their families, and every spinal cord injury, cerebral palsy, and Medicines in Development year costs the U.S. economy billions stroke. Among the many promising new For Neurological Disorders of dollars. Biopharmaceutical research medicines in development are: companies are developing 444 new • medicines to prevent and treat neu- A medicine that prompts the immune Application system to protect neurons affected by Submitted rological disorders. The medicines in development are either in human clinical ALS. Phase III trials or under review at the Food and • Gene therapy for the treatment of Phase II Drug Administration. They include: Alzheimer’s disease. Phase I • 82 medicines for Alzheimer’s disease, • Gene therapy to reverse the effects of which afflicts more than 5 million Parkinson’s disease. Americans. The new medicines being developed by 82 82 • 82 medicines for pain—100 million biopharmaceutical research companies U.S. adults experience chronic pain. reflect a growing understanding of the underlying mechanisms of neurological • 62 medicines for brain tumors—nearly disorders, which fuels scientific progress 62 70,000 Americans are diagnosed and pharmaceutical research. These medi- each year with a primary brain tumor. cines offer patients hope that more effec- • 38 medicines for multiple sclerosis, tive treatments may soon be available.
    [Show full text]
  • EMA401: an Old Antagonist of the AT2R for a New Indication in Neuropathic Pain
    Journal name: Journal of Pain Research Article Designation: PERSPECTIVES Year: 2017 Volume: 10 Journal of Pain Research Dovepress Running head verso: Keppel Hesselink and Schatman Running head recto: EMA401 in neuropathic pain open access to scientific and medical research DOI: http://dx.doi.org/10.2147/JPR.S128520 Open Access Full Text Article PERSPECTIVES EMA401: an old antagonist of the AT2R for a new indication in neuropathic pain Jan M Keppel Hesselink1 Abstract: EMA401 is an old molecule, synthesized by Parke-Davis in the last century and Michael E Schatman2 characterized at that time as an AT2R antagonist. Professor Maree Smith and her group from the University of Queensland (Australia) patented the drug and many related derivatives and 1Institute of Neuropathic Pain, Bosch en Duin, the Netherlands; other compounds with high affinity for the AT2R for the indication neuropathic pain in 2004, 2Department of Public Health and an example of drug repositioning. After some years of university work, the Australian biotech Community Medicine, Tufts University company Spinifex Pharmaceuticals took over further research and development and character- School of Medicine, Boston, MA, USA ized the S-enantiomer, code name EMA401, and related compounds in a variety of animal models for neuropathic and cancer pain. EMA401 was selected as the lead compound, based on high selectivity for the AT2R and good oral bioavailability (33%). EMA401, however, was only administered once in a chronic neuropathic pain model, and no data have been published in other pain models, or during steady state, although such data were available for the racemate EMA400 and some related compounds (EMA200, EMA400).
    [Show full text]